Stay updated on Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial.
Sign up to get notified when there's something new on the Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial. page.

Latest updates to the Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial. page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedExpanded the Location section by adding numerous site entries across multiple countries and states. This increases visibility of enrollment sites and provides more precise location information for potential participants.SummaryDifference4%

- Check22 days agoNo Change Detected
- Check29 days agoNo Change Detected
- Check36 days agoChange DetectedThe page now displays Revision: v3.3.2, replacing Revision: v3.3.1.SummaryDifference0.0%

- Check43 days agoChange DetectedPublication notes were added clarifying that publications may relate to the study results and are automatically filled from PubMed. The page revision was updated to v3.3.1.SummaryDifference0.3%

- Check50 days agoChange DetectedThe study location list now includes Tainan, Taiwan, 70457 instead of Tainan City, Taiwan, 70457, and the funding-status notice was removed.SummaryDifference0.1%

- Check65 days agoChange DetectedNo significant changes detected; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check72 days agoChange DetectedAdded Cali, Valle del Cauca Department, Colombia, 760042 to the locations list and removed Santiago de Cali, Valle del Cauca Department, Colombia, 760042.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial.
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial. page.